Do you work with fresh tumor tissue? MT Group does – we began collecting these cases for pharmaceutical R&D back in 2003 and this has remained a central part of our service ever since. And while R&D directions have changed, the need for high-quality fresh tumors has not. Many researchers are now not only evaluating novel compounds and biomarkers but also studying the tumor microenvironment, immunophenotyping, and conducting other pioneering science.
The MT Group has significantly grown its site network over the years, with more than 160 sites now actively screening for subjects. Both common and rare tumors are being collected, including bladder cancer, head & neck cancer, pancreatic cancer, and met lesions (even brain mets). Matched blood for liquid biopsy assay development and normal adjacent tissue are also available as is the comprehensive “MT Level” clinical metadata for which we are known.